19231-36-8

Basic information

• Product Name: 3-C-Methyl-3-O-methyl-2,6-dideoxy-D-xylo-hexopyranose
• Synonyms: 3-C-Methyl-3-O-methyl-2,6-dideoxy-D-xylo-hexopyranose;D-Arcanose
• CAS NO: 19231-36-8
• Molecular Formula: C₈H₁₆O₄
• Molecular Weight: 176.21024
• Mol File: 19231-36-8.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-C-Methyl-3-O-methyl-2,6-dideoxy-D-xylo-hexopyranose(CAS DataBase Reference)
• NIST Chemistry Reference: 3-C-Methyl-3-O-methyl-2,6-dideoxy-D-xylo-hexopyranose(19231-36-8)
• EPA Substance Registry System: 3-C-Methyl-3-O-methyl-2,6-dideoxy-D-xylo-hexopyranose(19231-36-8)

Safety Data

• Hazardous Substances Data: 19231-36-8(Hazardous Substances Data)

Upstream product

• 137101-02-1 methyl 2,6-anhydro-4-O-benzyl-3-C-methyl-2-thio-β-L-mannopyranoside 
• 137172-14-6 methyl 2,6-dideoxy-3-C-methyl-3-O-methyl-β-L-arabino-hexopyranoside 
• 144604-03-5 (10E)-10,11-didehydro-11-deoxy-6-O-methylerythromycin 
• 1092077-36-5 C₈H₁₄O₄ 
• 78443-22-8 C₃₇H₆₉ClN₂O₁₂ 
• 78443-20-6 4-O-acetyl-1-deoxy-1-(2-pyridylthio)-α-L-cladinoside 
• 26116-56-3 erythromycylamine 
• 30760-16-8 9-deoxo-9-iminoerythromycin A 
• 81103-11-9 clarithromycin 
• 97562-21-5 5-O-benzyl-4-O-(benzyloxymethyl)-2,6-dideoxy-3-C-methyl-3-O-methyl-L-ribohexose 
• 114-07-8 erythromycin 

Downstream Products

• 121203-17-6 1-deoxy-4-O-phenoxyacetyl-1-(2-pyridylthio)-β-cladinoside 
• 121203-06-3 1-deoxy-4-O-phenoxyacetyl-1-(2-pyridylthio)-α-cladinoside 
• 121230-89-5 2',4',4''-tri-O-acetyl-3-O-(4-O-phenoxyacetyl-α-L-cladinosyl)desmycosin 
• 121230-91-9 2',4',4''-tri-O-acetyl-20-deoxo-3-O-(4-O-phenoxyacetyl-α-L-cladinosyl)desmycosin 
• 121231-05-8 2',4',4''-tri-O-acetyl-19-deformyl-3-O-(4-O-phenoxyacetyl-α-L-cladinosyl)desmycosin 
• 121203-05-2 Phenoxy-acetic acid (2S,3S,4R)-6-hydroxy-4-methoxy-2,4-dimethyl-tetrahydro-pyran-3-yl ester 
• 121203-04-1 1,4-di-O-phenoxyacetyl-β-L-cladinose 

Relevant articles and documents

PROCESS FOR THE PRODUCTION OF TELITHROMYCIN

The present invention relates to a process for the preparation of erythromysin derivatives, in particular telithromycin of formula (I) and its pharmaceutically acceptable salts, providing the isolated intermediates in crystalline form of superior stability and purity.

Acid-catalyzed degradation of clarithromycin and erythromycin B: A comparative study using NMR spectroscopy

One of the major drawbacks in the use of the antibiotic erythromycin A is its extreme acid sensitivity, leading to degradation in the stomach following oral administration. The modern derivative clarithromycin degrades by a different mechanism and much more slowly. We have studied the pathway and kinetics of the acid-catalyzed degradation of clarithromycin and of erythromycin B, a biosynthetic precursor of erythromycin A which also has good antibacterial activity, using 1H NMR spectroscopy. Both drugs degrade by loss of the cladinose sugar ring and with similar rates of reaction. These results suggest that erythromycin B has potential as an independent therapeutic entity, with superior acid stability compared with erythromycin A and with the advantage over clarithromycin of being a natural product.

ACYCLIC STEREOSELECTION. 28. USE OF STEREOSELECTIVE ALDOL METHODOLOGY IN THE TOTAL SYNTHESIS OF CLADINOSE.

Reactions of (S)-2-benzyloxypropanal (4) with the lithium, magnesium, and zirconium enolates of methyl 2-methoxypropanoate (1) and with ketene acetals 2 and 3 have been studied and the stereostructures of the resulting products elucidated.The major stereo